Clinical Trials
Clinical trials are vital research studies that test new medical treatments, including innovative medications and devices. As a patient at the Southeastern Center for Headaches, you may have the opportunity to participate in advanced clinical trials, gaining access to the latest breakthroughs in headache and migraine care.
This clinical research study is evaluating new approaches to migraine management for children and teens ages 10 to 17 who experience headaches. Conducted in partnership with Cincinnati Children’s, the study explores whether coping skills training alone or combined with daily medication may help reduce headache severity and improve quality of life. Participants will complete a series of study visits and virtual coping skills sessions with a licensed teletherapist, along with brief daily headache tracking. Eligible families may receive compensation for their time and participation. This study reflects SECH’s ongoing commitment to advancing headache care through research and expanding treatment options for pediatric and adolescent patients.
Contact us to learn more:
Phone: 678-528-0961
Migraine Study
The PROSPECT-1 study is evaluating an investigational treatment to determine whether it may help reduce the number of migraine headache days in children and teens ages 6 to 17. This clinical trial is designed for pediatric patients who have been diagnosed with migraine for at least six months and experience multiple migraine days per month. The study aims to better understand treatment options for younger patients living with migraine and to advance care through ongoing research. Families interested in learning more can speak with a study representative to determine eligibility and review participation details.
Contact us to learn more:
Phone: 678-528-0961
PROSPECT-1 Pediatric Migraine Study
The PROSPECT-2 study is evaluating an investigational preventive treatment to determine whether it may help reduce migraine frequency in adolescents ages 12 to 17 living with chronic migraine. This clinical trial focuses on understanding the safety and effectiveness of eptinezumab for migraine prevention in younger patients who experience frequent, ongoing headaches. Through participation in this research, SECH continues its commitment to advancing migraine care and expanding future treatment options for adolescents and their families.
Contact us to learn more:
Phone: 678-528-0961
PROSPECT-2 Adolescent Chronic Migraine Study
If your young child has been diagnosed with ADHD and still struggles with hyperactivity and inattention, we ask you to consider taking part in the 812P401 Study. We are evaluating a study medication called SPN-812 to see if it has any effect on ADHD symptoms in preschool-aged children. SPN-812 is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in pediatric patients ages 6 to 17.
Contact us to learn more:
Phone: 678-528-0961
Clinical Trial: Treating ADHD in Children
